

SUPPLEMENT TO THE SUMMARY

**PART I OF THE PROSPECTUS FOR THE PUBLIC OFFERING OF SHARES OF
TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.**

The Supplement to this Summary is drawn up pursuant to Art. 85, Para. 2 of the POSA and in compliance with Commission Delegated Regulation (EU) № 382/2014 from the 7th of March 2014 supplementing Directive 2003/71 / EC of the European Parliament and the Council in respect to the regulatory technical standards for publishing a Supplement to the Prospectus and it only contains information relating to the occurrence of a significant new factor in the information contained in the approved Prospectus for the public offering of shares from the capital increase of Tchaikapharma High-Quality Medicines Inc., which may affect the assessment of the securities offered.

The ensuing new circumstance is the increase of the amount of the capital of Tchaikapharma High Quality Medicines Inc. by its own means through the capitalization of profits pursuant to Art. 192 in conjunction with Art. 197 of the Trade Act, as well as a change in the Company Regulations. The changes were made pursuant to the Decision of the General Meeting of shareholders on the 20th of April 2015. It is in the interest of investors before making an investment decision to familiarize themselves with the full text of the Prospectus comprising the Registration Document, the Document for the Offered Securities and the Summary and with the Supplement to the Prospectus consisting of a Supplement to the Registration Document, a Supplement to the Document for the Offered Securities and a Supplement to the Resume. The Prospectus contains the entire information which, according to the peculiarities of the company and the publicly offered securities, is required to make an investment decision, including the main risks related to the company and its activities. The Financial Supervision Commission has confirmed the Summary (as part of the Prospectus) with Decision № 304 - ПД from the 21st of April 2015 and the Supplement to the Summary (as part of the Supplement to the Prospectus) with Decision №/, which is not a recommendation to invest in the offered securities. The Financial Supervision Commission is not responsible for the correctness and completeness of the information contained therein.

The members of the Board of Directors of Tchaikapharma High Quality Medicines Inc. is jointly liable for the damages caused by false, misleading or incomplete data in the Supplement to the Summary. The legal representative of the issuer declares that, having taken all reasonable care, he is satisfied that such is the case, that the information contained in the Supplement to the Summary, to his best knowledge, is complete and correct, that it corresponds to the facts and contains no omission that is likely to affect its meaning and that the Supplement to the Summary complies with the requirements of the law. The draftsmen of the financial statements of the Company are jointly liable along with the persons referred to in the first sentence of Art. 81, Para. 3 of the POSA, for damages caused by false, misleading or incomplete data in the financial statements of the Company and the auditors - for damages caused by their audited financial statements.

The 30th of April 2015

1. THE SUPPLEMENT TO THE SUMMARY IS TO INTRODUCE AN ADDITION TO POINT B6. THE CONTENT OF POINT WILL APPEAR AS FOLLOWS:

| | |
|------------|---|
| B.6 | <p>Persons with direct or indirect interest in the capital of Issuer. Various voting rights. Availability of control.</p> <p>Tihomir Dimitrov Kamenov is a shareholder in Tchaikapharma High Quality Medicines Inc. and owns directly 47 616 000 dematerialized shares, representing 96% of the capital and votes in the General Meeting. Prof. Tony Ionkov Vekov owns 1 984 000 dematerialized shares representing 4% of the total issued shares of the company. All shares of Tchaikapharma High Quality Medicines Inc. have the same rights. The aforementioned majority shareholder does not have different rights from the other shareholders of the Company.</p> <p>Tihomir Dimitrov Kamenov exercises control over Tchaikapharma High Quality Medicines Inc. within the meaning of §1, Item 14 of the Supplementary Provisions of the Law on the Public Offering of Securities, as he directly owns 47 616 000 ordinary shares, representing 96% of the capital and votes in the General Meeting, he can appoint more than half of the members of the management body, and can exercise influence on the decision-making in connection with the operations of the Issuer.</p> |
|------------|---|

2. THE SUPPLEMENT TO THE SUMMARY IS TO INTRODUCE AN ADDITION TO POINT C1. THE CONTENT OF THE POINT WILL APPEAR AS FOLLOWS:

| | |
|------------|--|
| C.1 | <p>Type and class of the securities being offered and / or admitted to trading, including each of their identification number.</p> <p>There are 49 600 000 (forty-nine million six hundred thousand) ordinary registered shares, which give equal rights to the shareholders, where each ordinary share gives the right to one vote in the General Meeting, as well as the right to dividend and liquidation share in proportion to the nominal value of the share.</p> <p>The ISIN code of the issue is BG 1100008074.</p> <p>The nominal value of one share is BGN 1 (one).</p> |
|------------|--|

3. THE SUPPLEMENT TO THE SUMMARY IS TO INTRODUCE AN ADDITION TO POINT C3. THE CONTENT OF POINT WILL APPEAR AS FOLLOWS:

| | |
|------------|--|
| C.3 | <p>Number of the shares issued and paid in full and issued but not paid in full.</p> <p>As of the date of the preparation of this Summary, the share capital of Tchaikapharma High Quality Medicines Inc. amounted to BGN 49 600 000 (BGN forty-nine million six hundred thousand) distributed in BGN 49 600 000 (forty-nine million six hundred thousand) ordinary registered shares, with voting rights, dividend and liquidation share with a nominal value of BGN 1 (one) each.</p> <p>The issued capital of the Company is fully registered and paid.</p> |
|------------|--|

4. THE SUPPLEMENT TO THE SUMMARY IS TO INTRODUCE AN ADDITION TO POINT C4. THE CONTENT OF POINT WILL APPEAR AS FOLLOWS:

| | |
|------------|--|
| C.4 | <p>Description of the rights associated with the securities.</p> <p>All issued by the Company 49 600 000 ordinary registered shares are with a nominal value of BGN 1 (one) each and are of the same class. Shares give equal rights to shareholders, namely:</p> <ol style="list-style-type: none"> 1. Voting right 2. The right to a dividend and liquidation share in proportion to the nominal value 3. The right of every shareholder in a capital increase to acquire shares corresponding to his/her share in the capital before the increase 4. The right of each shareholder to participate in the management of the company, to elect and be elected in the management bodies 5. The right to information, including the right to get acquainted with the materials on the announced agenda of the General Meeting of the shareholders (GMS) and to obtain them on demand 6. The right to seek judicial revision of the decisions of the General Meeting of the shareholders when they do not comply with the law and the regulations. |
|------------|--|

5. THE SUPPLEMENT TO THE SUMMARY IS TO INTRODUCE AN ADDITION TO POINT D.2a. THE CONTENT OF POINT WILL APPEAR AS FOLLOWS:

| | |
|-------------|---|
| D.2a | <p>Reasons for the offer, the use of proceeds and their estimated net value.</p> <p>This issue of 49 600 000 (forty-nine million six hundred thousand) shares is offered pursuant to the decision of the GMS of Tchaikapharma High Quality Medicines Inc. from the 10th of September 2015 and the decision of the GMS of Tchaikapharma High Quality Medicines Inc. from the 30th of April 2015. The Board of Directors of Tchaikapharma High Quality</p> |
|-------------|---|

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC

| | |
|--|---|
| | <p>Medicines Inc. wishes the Company to become public in order to increase its popularity among the potential customers and society as a whole. The public status of the Company will help strengthen its competitive position and image, and can be an important element of the planned marketing campaign to promote the name Tchaikapharma High Quality Medicines Inc. in the outlook of a broad range of potential customers of the offered by the Company products and services. Secondly, the public status of the Company and the registration of its shares for trading on the BSE, will create conditions for achieving liquidity and the formation of the market price of its stock shares.</p> |
|--|---|

INVESTORS CAN GET ACQUAINTED WITH THE ORIGINAL PROSPECTUS AND THE SUPPLEMENT TO THE PROSPECTUS AND WITH THE DOCUMENTS, TO WHICH THEY REFER, AS WELL AS TO OBTAIN FURTHER INFORMATION ON THE PROSPECTUS AND THE SUPPLEMENT TO THE PROSPECTUS IN THE OFFICE OF TCHAIKAPHARMA HIGH QUALITY MEDICINES INC:

Sofia, 1172

District Izgrev, №1 G.M.Dimitrov Blvd.

as well as on the website: www.tchaikapharma.com

The Supplement to the Summary was drafted by:

Biser Georgiev [signature]

Dimitar Stoyanov [signature]

Biser Ivanov [signature]

The undersigned, as a person representing the Company, with his signature declares that the Supplement to the Summary meets the requirements of the law.

Biser Georgiev[signature]
CEO
of Tchaikapharma High Quality Medicines Inc.